U.S. Targeted DNA-RNA Sequencing Market: By Workflow, Product, Application, Type, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035

The U.S.-targeted DNA-RNA sequencing market represents a dominant and rapidly expanding segment within the broader genomics and molecular diagnostics landscape. In 2025, the market is valued at approximately USD 4.92 billion, reflecting strong clinical and research adoption of targeted sequencing technologies across oncology, genetic disease analysis, and translational medicine.

Looking ahead, the market is projected to experience substantial expansion, reaching an estimated valuation of USD 28.54 billion by 2035. This trajectory corresponds to a robust compound annual growth rate (CAGR) of 19.22% during the forecast period from 2026 to 2035. Such sustained growth highlights the accelerating penetration of sequencing-based diagnostics and the continued shift toward precision medicine frameworks within the U.S. healthcare system.

Noteworthy Market Developments

The U.S. targeted DNA-RNA sequencing market operates within a highly consolidated oligopolistic structure, where a small number of dominant players control a significant portion of the market. This competitive landscape is characterized by high entry barriers, strong intellectual property protection, and substantial capital requirements, which collectively limit the number of viable competitors.

Companies such as Illumina and Thermo Fisher Scientific play a central role in this ecosystem, with Illumina maintaining a particularly strong position due to its sequencing by synthesis (SBS) chemistry, which has become widely regarded as the industry standard for high-throughput sequencing. This technology underpins a large share of sequencing workflows in the U.S., and Illumina is estimated to control approximately 78% of the high-throughput sequencing instrument market.

At the same time, emerging competitors such as Oxford Nanopore Technologies (ONT) and Pacific Biosciences (PacBio) are actively expanding their presence, particularly in the targeted long-read sequencing segment. These companies are focusing on overcoming the limitations of short-read sequencing by offering improved resolution in structurally complex genomic regions.

Core Growth Drivers

The demand for targeted DNA-RNA sequencing in the U.S. is strongly driven by the substantial and steadily increasing burden of cancer, with more than 2 million new cancer diagnoses reported annually. This high incidence has fundamentally reshaped oncology practice, accelerating a transition away from traditional broad-spectrum systemic therapies toward more precise, biomarker-driven treatment strategies. As a result, genomic insights have become essential in guiding therapeutic decisions, enabling clinicians to tailor treatments based on the specific molecular characteristics of each patient's tumor.

Emerging Opportunity Trends

The evolution of precision oncology has significantly reshaped Total Addressable Market (TAM) penetration within the U.S. targeted DNA-RNA sequencing market. Precision oncology is no longer considered a niche or supplementary approach within cancer care; instead, it has become a foundational standard of care in many clinical settings. This shift reflects a broader transformation in oncology, where treatment decisions are increasingly guided by the molecular and genetic characteristics of individual tumors rather than solely by their anatomical origin.

Barriers to Optimization

Despite significant technological advancements, the U.S.-targeted DNA-RNA sequencing market in 2025 continues to face notable vulnerabilities stemming from broader macro-level supply chain fragilities. Even as sequencing technologies have become more efficient, automated, and scalable, the ecosystem supporting these systems remains highly dependent on a tightly integrated global supply network. This dependence creates exposure to disruptions that can impact availability, cost structures, and operational continuity across the sequencing value chain.

Detailed Market Segmentation

By product, the next-generation sequencing (NGS) segment recorded the highest market share in 2025, reflecting its strong adoption across clinical, research, and translational applications. NGS platforms have become the preferred technology for high-throughput genetic analysis due to their ability to simultaneously sequence millions of DNA or RNA fragments with high accuracy and cost efficiency. This scalability has made NGS particularly valuable in areas such as oncology, rare disease diagnostics, and infectious disease surveillance, where comprehensive genomic insights are essential.

By workflow, the sequencing segment accounted for the largest market share in 2025, reflecting its central role in the overall DNA and RNA analysis process. As the core step where raw biological information is translated into readable genetic data, sequencing remains the most resource-intensive and technologically advanced phase of the workflow. Its dominance is reinforced by continuous demand from clinical diagnostics, research laboratories, and pharmaceutical applications, all of which depend on high-quality sequencing outputs to drive downstream analysis and decision-making.

By application, the drug discovery segment accounted for the largest share of the market in 2025, driven by the increasing reliance on advanced genomic technologies to identify and validate novel therapeutic targets. Pharmaceutical and biotechnology companies are placing greater emphasis on precision medicine approaches, where understanding the genetic and molecular basis of diseases is essential for developing more effective and targeted treatments. As a result, genomic sequencing and biomarker identification have become integral components of early-stage drug development, enabling researchers to streamline candidate selection and improve the probability of clinical success.

By type, the DNA-based targeted sequencing segment held the leading position in the market in 2025, primarily due to the inherent advantages of DNA as a molecular material in clinical applications. One of the key factors driving this dominance is the high stability of DNA molecules, especially when compared to other biomolecules such as RNA, which are more prone to degradation. This stability makes DNA particularly well-suited for use in preserved tissue samples, where maintaining molecular integrity over time is critical for accurate analysis.

Segment Breakdown

By Product

• NGS
• Method
• Exome Sequencing
• Enrichment Sequencing
• Amplicon Sequencing
• Others
• Application
• Cancer Gene Sequencing
• Inherited Disease Screening
• Drug Development
• Forensic Genomics
• 16S ribosomal RNA (rRNA) sequencing
• Others

By Workflow

• Pre-Sequencing
• Sequencing
• Data Analysis

By Type

• DNA-Based Targeted Sequencing
• RNA-Based Targeted Sequencing

By Application

• Human Biomedical Research
• Plant and Animal Sciences
• Drug Discovery
• Others

By End User

• Academic Research
• Hospitals and Clinics
• Pharma and Biotech Entities
• Others

Leading Market Participants

• Abbott PerkinElmer, Inc.
• DNASTAR, Inc.
• PierianDx
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Other Prominent Players